Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Rhythm Pharmaceuticals, Inc. (RYTM : NSDQ)
 
 • Company Description   
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA.

Number of Employees: 76

 
 • Price / Volume Information   
Yesterday's Closing Price: $86.70 Daily Weekly Monthly
20 Day Moving Average: 877,488 shares
Shares Outstanding: 63.62 (millions)
Market Capitalization: $5,515.94 (millions)
Beta: 2.26
52 Week High: $94.80
52 Week Low: $40.61
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 37.57% 32.86%
12 Week 40.43% 18.51%
Year To Date 54.88% 48.96%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
222 BERKELEY STREET 12TH FLOOR
-
BOSTON,MA 02116
USA		 ph: 857-264-4280
fax: 857-264-4299		 dconnolly@rhythmtx.com http://www.rhythmtx.com
 
 • General Corporate Information   
Officers
David P. Meeker - Chief Executive Officer; Chairman and Director
Hunter Smith - Chief Financial Officer
Christopher P. German - Corporate Controller
Edward T. Mathers - Director
Stuart Arbuckle - Director

Peer Information
Rhythm Pharmaceuticals, Inc. (CORR.)
Rhythm Pharmaceuticals, Inc. (RSPI)
Rhythm Pharmaceuticals, Inc. (CGXP)
Rhythm Pharmaceuticals, Inc. (BGEN)
Rhythm Pharmaceuticals, Inc. (GTBP)
Rhythm Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 76243J105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 63.62
Most Recent Split Date: (:1)
Beta: 2.26
Market Capitalization: $5,515.94 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.76 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 26.81% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 291.02
Price/Cash Flow: -
Price / Sales: 40.30
EPS Growth
vs. Year Ago Period: 65.53%
vs. Previous Quarter: -12.50%
Sales Growth
vs. Year Ago Period: 25.94%
vs. Previous Quarter: -21.82%
ROE
06/30/25 - -
03/31/25 - -739.62
12/31/24 - -778.59
ROA
06/30/25 - -
03/31/25 - -44.27
12/31/24 - -74.64
Current Ratio
06/30/25 - -
03/31/25 - 3.30
12/31/24 - 3.24
Quick Ratio
06/30/25 - -
03/31/25 - 3.13
12/31/24 - 3.08
Operating Margin
06/30/25 - -
03/31/25 - -123.26
12/31/24 - -200.24
Net Margin
06/30/25 - -
03/31/25 - -123.26
12/31/24 - -200.24
Pre-Tax Margin
06/30/25 - -
03/31/25 - -123.19
12/31/24 - -200.00
Book Value
06/30/25 - -
03/31/25 - 0.30
12/31/24 - 0.35
Inventory Turnover
06/30/25 - -
03/31/25 - 0.89
12/31/24 - 1.01
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©